This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
zacks-rank: Archive
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of -240.91% and 85.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
QURENegative Net Change ALGSPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Vital Farms (VITL) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Vital Farms (VITL) delivered earnings and revenue surprises of 53.33% and 3.60%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
VITLPositive Net Change MKCNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Vertex (VERX) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Vertex (VERX) delivered earnings and revenue surprises of 7.14% and 1.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
VERXPositive Net Change PDPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 22.86% and 17.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
VRDNPositive Net Change URGNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Starwood Property Trust (STWD) Beats Q4 Earnings Estimates
by Zacks Equity Research
Starwood Property Trust (STWD) delivered earnings and revenue surprises of 4.35% and 3.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
STWDPositive Net Change ACRNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 104.55% and 173.66%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
TRDANegative Net Change AGENPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Verve Therapeutics (VERV) delivered earnings and revenue surprises of 19.44% and 90.39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
VERVPositive Net Change OABINegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Macerich (MAC) Q4 FFO Match Estimates
by Zacks Equity Research
Macerich (MAC) delivered FFO and revenue surprises of 0% and 16.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
MACNegative Net Change JEFPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Papa John's (PZZA) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Papa John's (PZZA) delivered earnings and revenue surprises of 31.25% and 3.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
PZZAPositive Net Change DRIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Kimbell Royalty (KRP) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kimbell Royalty (KRP) delivered earnings and revenue surprises of -152.63% and 16.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
KRPNegative Net Change REXNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of -79.41% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
NVCRPositive Net Change SPROPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
PENN Entertainment (PENN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
PENN Entertainment (PENN) delivered earnings and revenue surprises of -7.32% and 0.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
PENNPositive Net Change SKLZPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 68.75% and 313.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
ACRSNegative Net Change XERSNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Warner Bros. Discovery (WBD) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Warner Bros. Discovery (WBD) delivered earnings and revenue surprises of -600% and 3.17%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
WBDPositive Net Change FUBOPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -80% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
IRWDPositive Net Change ECORPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -15.79% and 43.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
KYMRPositive Net Change IMTXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Palmer Square Capital BDC Inc. (PSBD) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Palmer Square Capital BDC Inc. (PSBD) delivered earnings and revenue surprises of -4.17% and 0.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
PSBDNegative Net Change FDUSPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -9.38% and 47.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
TNGXNegative Net Change ADCTPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of -11.36% and 39.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
CCCCPositive Net Change SGMONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Evergy Inc (EVRG) Q4 Earnings Lag Estimates
by Zacks Equity Research
Evergy (EVRG) delivered earnings and revenue surprises of -2.78% and 5.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
EVRGNegative Net Change AQNPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Hayward Holdings, Inc. (HAYW) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Hayward Holdings (HAYW) delivered earnings and revenue surprises of 12.50% and 8.38%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
HAYWNegative Net Change MGNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Aaon (AAON) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Aaon (AAON) delivered earnings and revenue surprises of -44.44% and 8.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
AAONNegative Net Change ORNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Cogent Communications (CCOI) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cogent (CCOI) delivered earnings and revenue surprises of 25.41% and 1.88%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
CCOINegative Net Change ATNIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Smucker (SJM) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Smucker (SJM) delivered earnings and revenue surprises of 10.13% and 1.59%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?
SJMNegative Net Change UNFINegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Ardagh Metal Packaging S.A. (AMBP) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Ardagh Metal Packaging (AMBP) delivered earnings and revenue surprises of 50% and 4.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
AMBPPositive Net Change PLUGPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank